肝細胞癌活體肝移植的研究現狀_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

徐驍 ^1,2 ,  王琨 ¹ ,  鄭樹森 ^1,2

1. ;
2. ;

Corresponding?author：

鄭樹森, Email: shusenzheng@zju.edu.cn

Keywords：

DOI：

10.7507/1007-9424.201706116

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 徐驍, 王琨, 鄭樹森. 肝細胞癌活體肝移植的研究現狀. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(8): 916-919. doi: 10.7507/1007-9424.201706116 Copy

1.	Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett, 2017, 401: 63-71.
2.	Sung PS, Yang H, Na GH, et al. Long-term outcome of liver resection versus transplantation for hepatocellular carcinoma in a region where living donation is a main source. Ann Transplant, 2017, 22: 276-284.
3.	Lee SG, Moon DB, Hwang S, et al. Liver transplantation in Korea: past, present, and future. Transplant Proc, 2015, 47(3): 705-708.
4.	Umeshita K, Inomata Y, Furukawa H, et al. Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society. Hepatol Res, 2016, 46(12): 1171-1186.
5.	Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery, 1991, 110(4): 726-735.
6.	Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334(11): 693-699.
7.	Chen LP, Li C, Wen TF, et al. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma? Pak J Med Sci, 2015, 31(4): 763-769.
8.	Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery, 2013, 154(5): 1053-1060.
9.	Lee SD, Lee B, Kim SH, et al. Proposal of new expanded selection criteria using total tumor size and ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transplant, 2016, 6(2): 411-422.
10.	Hsu CC, Chen CL, Wang CC, et al. Combination of FDG-PET and UCSF criteria for predicting HCC recurrence after living donor liver transplantation. Transplantation, 2016, 100(9): 1925-1932.
11.	Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85(12): 1726-1732.
12.	Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS One, 2014, 9(3): e93128.
13.	Lee KW, Suh SW, Choi Y, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transpl, 2017, 23(1): 19-27.
14.	Levi Sandri GB, Ettorre GM, Colasanti M, et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr, 2017, 6(1): 44-48.
15.	Choi JY, Yu JI, Park HC, et al. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transpl, 2017, 23(4): 545-551.
16.	Akamatsu N, Sugawara Y, Kokudo N. Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol, 2014, 6(9): 626-631.
17.	Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant, 2007, 7(6): 1601-1608.
18.	Li CX, Ling CC, Shao Y, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol, 2016, 65(5): 944-952.
19.	Man K, Shih KC, Ng KT, et al. Molecular signature linked to acute phase injury and tumor invasiveness in small-for-size liver grafts. Ann Surg, 2010, 251(6): 1154-1161.
20.	Shi JH, Huitfeldt HS, Suo ZH, et al. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl, 2011, 17(7): 866-874.
21.	Man K, Fan ST, Lo CM, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg, 2003, 237(2): 256-264.
22.	Ng KT, Lo CM, Wong N, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation. Oncotarget, 2016, 7(15): 19824-19839.
23.	Mangus RS, Fridell JA, Vianna RM, et al. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation, 2008, 85(10): 1496-1499.
24.	Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
25.	Xiao GQ, Song JL, Shen S, et al. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation. World J Gastroenterol, 2014, 20(31): 10953-10959.
26.	Sandhu L, Sandroussi C, Guba M, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl, 2012, 18(3): 315-322.
27.	Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation, 2014, 97(1): 71-77.
28.	Kulik LM, Fisher RA, Rodrigo DR, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant, 2012, 12(11): 2997-3007.
29.	Lo CM, Fan ST, Liu CL, et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg, 2007, 94(1): 78-86.
30.	Zakaria HM, Shoreem HA, Aziz AA, et al. Pattern of hepatocellular carcinoma recurrence following living donor liver transplantation. Surg Pract, 2016, 20(1): 18-26.
31.	Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology, 2011, 53(5): 1570-1579.
32.	Na GH, Hong TH, You YK, et al. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol, 2016, 22(25): 5790-5799.
33.	Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American Series. Ann Surg Oncol, 2015, 22(7): 2286-2294.
34.	Rotellar F, Pardo F, Benito A, et al. Totally laparoscopic right hepatectomy for living donor liver transplantation: Analysis of a preliminary experience on 5 consecutive cases. Transplantation, 2017, 101(3): 548-554.
35.	Chan SC, Sharr WW, Cheung TT, et al. Retrohepatic vena cava deroofing in living donor liver transplantation for caudate hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2013, 12(5): 552-555.
36.	Moon DB, Lee SG, Hwang S, et al. No-touch en bloc right lobe living-donor liver transplantation with inferior vena cava replacement for hepatocellular carcinoma close to retrohepatic inferior vena cava: case report. Transplant Proc, 2013, 45(8): 3135-3139.
37.	Lee EC, Kim SH, Lee SD, et al. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol, 2016, 22(14): 3803-3812.
38.	中華醫學會器官移植學分會, 中華醫學會外科學分會移植學組, 中國醫師協會器官移植醫師分會. 中國肝癌肝移植臨床實踐指南. 中華外科雜志, 2014, 52(10): 721-725.
39.	Kim JM, Joh JW, Kim SJ, et al. Steroid withdrawal in adult liver transplantation: occurrence at a single center. Transplant Proc, 2010, 42(10): 4132-4136.
40.	Hatem R, El Botty R, Chateau-Joubert S, et al. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget, 2016, 7(30): 48206-48219.
41.	Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl, 2016, 22(5): 627-634.
42.	Lee KW, Seo YD, Oh SC, et al. What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma? Hepatol Res, 2016, 46(6): 593-600.
43.	Jeng LB, Thorat A, Hsieh YW, et al. Experience of using everolimus in the early stage of living donor liver transplantation. Transplant Proc, 2014, 46(3): 744-748.
44.	Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. Transplantation, 2016, 100(1): 116-125.
45.	Yoo EJ, Shin HS, Kim SU, et al. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther, 2013, 6: 755-759.
46.	Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant, 2010, 8(4): 307-313.
47.	Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology, 2007, 45(2): 269-276.
48.	S?derdahl G, B?ckman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int, 2006, 19(4): 288-294.

1. Chen W, Zheng R, Zhang S, et al. Cancer incidence and mortality in China, 2013. Cancer Lett, 2017, 401: 63-71.
2. Sung PS, Yang H, Na GH, et al. Long-term outcome of liver resection versus transplantation for hepatocellular carcinoma in a region where living donation is a main source. Ann Transplant, 2017, 22: 276-284.
3. Lee SG, Moon DB, Hwang S, et al. Liver transplantation in Korea: past, present, and future. Transplant Proc, 2015, 47(3): 705-708.
4. Umeshita K, Inomata Y, Furukawa H, et al. Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society. Hepatol Res, 2016, 46(12): 1171-1186.
5. Penn I. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery, 1991, 110(4): 726-735.
6. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334(11): 693-699.
7. Chen LP, Li C, Wen TF, et al. Can living donor liver transplantation offer similar outcomes to deceased donor liver transplantation using expanded selection criteria for hepatocellular carcinoma? Pak J Med Sci, 2015, 31(4): 763-769.
8. Kaido T, Ogawa K, Mori A, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery, 2013, 154(5): 1053-1060.
9. Lee SD, Lee B, Kim SH, et al. Proposal of new expanded selection criteria using total tumor size and ¹⁸F-fluorodeoxyglucose-positron emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National Cancer Center Korea criteria. World J Transplant, 2016, 6(2): 411-422.
10. Hsu CC, Chen CL, Wang CC, et al. Combination of FDG-PET and UCSF criteria for predicting HCC recurrence after living donor liver transplantation. Transplantation, 2016, 100(9): 1925-1932.
11. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85(12): 1726-1732.
12. Chen J, Xu X, Wu J, et al. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS One, 2014, 9(3): e93128.
13. Lee KW, Suh SW, Choi Y, et al. Macrovascular invasion is not an absolute contraindication for living donor liver transplantation. Liver Transpl, 2017, 23(1): 19-27.
14. Levi Sandri GB, Ettorre GM, Colasanti M, et al. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr, 2017, 6(1): 44-48.
15. Choi JY, Yu JI, Park HC, et al. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus. Liver Transpl, 2017, 23(4): 545-551.
16. Akamatsu N, Sugawara Y, Kokudo N. Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol, 2014, 6(9): 626-631.
17. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant, 2007, 7(6): 1601-1608.
18. Li CX, Ling CC, Shao Y, et al. CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol, 2016, 65(5): 944-952.
19. Man K, Shih KC, Ng KT, et al. Molecular signature linked to acute phase injury and tumor invasiveness in small-for-size liver grafts. Ann Surg, 2010, 251(6): 1154-1161.
20. Shi JH, Huitfeldt HS, Suo ZH, et al. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl, 2011, 17(7): 866-874.
21. Man K, Fan ST, Lo CM, et al. Graft injury in relation to graft size in right lobe live donor liver transplantation: a study of hepatic sinusoidal injury in correlation with portal hemodynamics and intragraft gene expression. Ann Surg, 2003, 237(2): 256-264.
22. Ng KT, Lo CM, Wong N, et al. Early-phase circulating miRNAs predict tumor recurrence and survival of hepatocellular carcinoma patients after liver transplantation. Oncotarget, 2016, 7(15): 19824-19839.
23. Mangus RS, Fridell JA, Vianna RM, et al. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation, 2008, 85(10): 1496-1499.
24. Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217.
25. Xiao GQ, Song JL, Shen S, et al. Living donor liver transplantation does not increase tumor recurrence of hepatocellular carcinoma compared to deceased donor transplantation. World J Gastroenterol, 2014, 20(31): 10953-10959.
26. Sandhu L, Sandroussi C, Guba M, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl, 2012, 18(3): 315-322.
27. Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation. Transplantation, 2014, 97(1): 71-77.
28. Kulik LM, Fisher RA, Rodrigo DR, et al. Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant, 2012, 12(11): 2997-3007.
29. Lo CM, Fan ST, Liu CL, et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg, 2007, 94(1): 78-86.
30. Zakaria HM, Shoreem HA, Aziz AA, et al. Pattern of hepatocellular carcinoma recurrence following living donor liver transplantation. Surg Pract, 2016, 20(1): 18-26.
31. Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology, 2011, 53(5): 1570-1579.
32. Na GH, Hong TH, You YK, et al. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation. World J Gastroenterol, 2016, 22(25): 5790-5799.
33. Sapisochin G, Goldaracena N, Astete S, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American Series. Ann Surg Oncol, 2015, 22(7): 2286-2294.
34. Rotellar F, Pardo F, Benito A, et al. Totally laparoscopic right hepatectomy for living donor liver transplantation: Analysis of a preliminary experience on 5 consecutive cases. Transplantation, 2017, 101(3): 548-554.
35. Chan SC, Sharr WW, Cheung TT, et al. Retrohepatic vena cava deroofing in living donor liver transplantation for caudate hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int, 2013, 12(5): 552-555.
36. Moon DB, Lee SG, Hwang S, et al. No-touch en bloc right lobe living-donor liver transplantation with inferior vena cava replacement for hepatocellular carcinoma close to retrohepatic inferior vena cava: case report. Transplant Proc, 2013, 45(8): 3135-3139.
37. Lee EC, Kim SH, Lee SD, et al. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol, 2016, 22(14): 3803-3812.
38. 中華醫學會器官移植學分會, 中華醫學會外科學分會移植學組, 中國醫師協會器官移植醫師分會. 中國肝癌肝移植臨床實踐指南. 中華外科雜志, 2014, 52(10): 721-725.
39. Kim JM, Joh JW, Kim SJ, et al. Steroid withdrawal in adult liver transplantation: occurrence at a single center. Transplant Proc, 2010, 42(10): 4132-4136.
40. Hatem R, El Botty R, Chateau-Joubert S, et al. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers. Oncotarget, 2016, 7(30): 48206-48219.
41. Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl, 2016, 22(5): 627-634.
42. Lee KW, Seo YD, Oh SC, et al. What is the best immunosuppressant combination in terms of antitumor effect in hepatocellular carcinoma? Hepatol Res, 2016, 46(6): 593-600.
43. Jeng LB, Thorat A, Hsieh YW, et al. Experience of using everolimus in the early stage of living donor liver transplantation. Transplant Proc, 2014, 46(3): 744-748.
44. Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: A randomized, multicenter, open-label phase 3 trial. Transplantation, 2016, 100(1): 116-125.
45. Yoo EJ, Shin HS, Kim SU, et al. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther, 2013, 6: 755-759.
46. Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant, 2010, 8(4): 307-313.
47. Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology, 2007, 45(2): 269-276.
48. S?derdahl G, B?ckman L, Isoniemi H, et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int, 2006, 19(4): 288-294.

Previous Article
活體肝移植在中國的發展與前景
Next Article
兒童活體肝移植的發展概況

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

肝細胞癌活體肝移植的研究現狀

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content